Talk:Placenta - Maternal Decidua
| About Discussion Pages |
|---|
Glossary Links
Cite this page: Hill, M.A. (2026, October 1) Embryology Placenta - Maternal Decidua. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/Talk:Placenta_-_Maternal_Decidua |
2011
Decidualisation and angiogenesis
Best Pract Res Clin Obstet Gynaecol. 2011 Jun;25(3):259-71. Epub 2010 Dec 8.
Plaisier M. Source Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands. Margreetp@hotmail.com
Abstract
The timing of decidualisation and vascular processes during the implantation period is of paramount importance for the development of a receptive endometrium suitable for implantation. The endometrium transforms during the secretory phase into a well-vascularised receptive tissue characterised by increased vascular permeability, oedema, proliferation and differentiation of stromal cells into decidual cells, invasion of leucocytes, vascular remodelling and angiogenesis. Decidualisation continues in the presence of conception and an influx of immune cells, trophoblasts and vascular adaptation will occur. Vascular changes include spiral artery remodelling, angiogenesis and the induction of angiogenic factors. Disturbances in uterine blood supply are associated with first-trimester miscarriages and third-trimester perinatal morbidity and mortality caused by pre-eclampsia and foetal growth restriction. This article assesses decidual vascular changes during human implantation, and evaluates the involvement of angiogenesis in the pathogenesis of miscarriages, pre-eclampsia and intrauterine growth restriction.
Copyright © 2010 Elsevier Ltd. All rights reserved.
PMID: 21144801
http://www.ncbi.nlm.nih.gov/pubmed/21144801
SERPINE2, an inhibitor of plasminogen activators, is highly expressed in the human endometrium during the secretory phase
Reprod Biol Endocrinol. 2011 Mar 23;9:38.
Lee RK, Fan CC, Hwu YM, Lu CH, Lin MH, Chen YJ, Li SH. Source Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: SERPINE2, also known as protease nexin-1, belongs to the serine protease inhibitor (SERPIN) superfamily. It is one of the potent SERPINs that modulates the activity of plasminogen activators (PAs). PAs and their SERPIN inhibitors, such as SERPINB2 and SERPINE1, were expressed in the human endometrium and were implicated in implantation. However, expression data about SERPINE2 in the human endometrium is still unknown. Thus, we conducted an investigation to reveal the spatiotemporal and cellular expression of SERPINE2 in the human uterus during the menstrual cycle.
METHODS: Seven patients who underwent a hysterectomy and samples of 120 archived patients' endometrial curettage or parts of the uterus that were formalin-fixed and embedded in paraffin. Western blotting was performed to evaluate the specificity and sensitivity of the antibody. Immunohistochemistry was conducted to localize the SERPINE2 expression site. Quantitative analysis was conducted to evaluate expression levels of SERPINE2 in various sub-phases of the menstrual cycle.
RESULTS: The SERPINE2 protein was primarily detected in the uterine fluid during the mid- and late-secretory phases of the menstrual cycle. It was predominantly expressed in the luminal and glandular epithelium, less in the myometrium, and only dispersedly in certain stromal cells throughout the menstrual cycle. A quantitative analysis of expression levels of SERPINE2 in the glandular epithelium revealed that it was highly expressed in the endometrium during the secretory phase compared to the proliferative phase.
CONCLUSIONS: The SERPINE2 protein is highly expressed in the endometrium during the secretory phase, indicating that it may participate in tissue remodeling involved in implantation.
PMID: 21426587
